Etat de stress post-traumatique (ESPT) : un syndrome du lobe temporal droit ? – Post-traumatic stress disorder: a right temporal lobe syndrome?

Post-traumatic stress disorder: a right temporal lobe syndrome?
B Engdahl, A C Leuthold, H-R M Tan, S M Lewis, A M Winskowski, T N Dikel and A P Georgopoulos
In a recent paper (Georgopoulos et al 2010 J. Neural Eng. 7 016011) we reported on the power of the magnetoencephalography (MEG)-based synchronous neural interactions (SNI) test to differentiate post-traumatic stress disorder (PTSD) subjects from healthy control subjects and to classify them with a high degree of accuracy.
Here we show that the main differences in cortical communication circuitry between these two groups lie in the miscommunication of temporal and parietal and/or parieto-occipital right hemispheric areas with other brain areas.
This lateralized temporal-posterior pattern of miscommunication was very similar but was attenuated in patients with PTSD in remission.
These findings are consistent with observations (Penfield 1958
Proc. Natl Acad. Sci. USA 44 51–66, Penfield and Perot 1963 Brain 86 595–696, Gloor 1990 Brain 113 1673–94, Banceaud et al 1994 Brain 117 71–90, Fried 1997 J. Neuropsychiatry Clin. Neurosci. 9 420–8) that electrical stimulation of the temporal cortex in awake human subjects, mostly in the right hemisphere, can elicit the re-enactment and re-living of past experiences.
Based on these facts, we attribute our findings to the re-experiencing component of PTSD and hypothesize that it reflects an involuntarily persistent activation of interacting neural networks involved in experiential consolidation.
Published 28 octobre 2010
Pour lire l’article, cliquez sur le logo de Journal of Neural Engineering

Ecstasy Shows Promise in Relieving PTSD by John Cloud

By John Cloud Tuesday, Jul. 20, 2010

On July 19, the Journal of Psychopharmacology reported the results of the first randomized, controlled trial of ecstasy, which is known to chemists as 3,4-methylene dioxyme thamphetamine, or MDMA. The study’s authors — led by Dr. Michael Mithoefer, a South Carolina psychiatrist — gave MDMA or a placebo to patients with posttraumatic stress disorder (PTSD) whose condition had not been alleviated by any standard combination of psychotherapy and antidepressants. The new paper showed that ecstasy is not only safe when administered in controlled settings but also remarkably effective in treating PTSD in conjunction with psychotherapy.

Given the controversial nature of their study, the authors write in an all-business tone — the word ecstasy does not appear anywhere in the article. They begin by noting that PTSD is a serious mental-health problem — it is diagnosed in roughly 8% of Americans and as many as 1 in 5 U.S. servicemen and women returning from Afghanistan and Iraq — and that we have little clue about how to treat it.

Read more:clic on Time